System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Marina Pulido is an expert in Oncology at Institut Bergonié (France). Marina Pulido has authored 57 publications, the most recent in 2026, and is an investigator in 9 clinical trials. SLR score: 235 (community average: 125). How the SLR is computed.

LeadR Profile

Marina Pulido Institut Bergonié France
235 ScienceLeadR Reputation 235

Unlock

Register Login
Network Map

Oncology

Subspecialties: Biochemistry - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2006 - 2026
Source: PubMed

Institut Bergonié

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 57

Citations

Citations: 1 785 1st author: 4 Last author: 1 Unique author: 0

Main journals

J Clin Oncol 7
Rev Epidemiol Sante Publique 6
Ann Oncol 5
Cancer Res 5
Clin Cancer Res 3

Best Journals

Lancet Oncol 2
J Clin Oncol 1
Mol Cancer 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older - final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study.
PMID 42579983 — quality of life, breast neoplasms, neoplasms, hormones, aged, breast, therapeutics		Breast20261
Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial.
PMID 42242004 — breast neoplasms, neoplasms, breast, therapeutics, plasma		ESMO Open20260
Recommendations for sustainable control of cattle tick, Rhipicephalus (Boophilus) microplus (Canestrini, 1887) in Latin America and the Caribbean.
PMID 42097525 — acaricides, parasitic diseases, parasites, drug resistance		Int J Parasitol20260
Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial.
PMID 39978376 — headache, triple negative breast neoplasms, immunohistochemistry, breast neoplasms, androgens, receptors, androgen, neoplasms, drug therapy, drug-related side effects and adverse reactions, breast, capecitabine, chemotherapy		Lancet Oncol Top journal202518
Health literacy and the use of digital tools in older patients with cancer and their younger counterparts: A multicenter, nationwide study.
PMID 39303502 — neoplasms, aged, counseling, patient education as topic, health literacy, literacy		Patient Educ Couns20242

Clinical Studies 9

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 7
N/A 1
Phase 1/Phase 2 1

By status:

Completed 8
Recruiting 1

By type:

Interventional 9

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 1
multicentric5to9 3
multicentricup10 1

Main Topics

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS